Rodolfo Guelman
YOU?
Author Swipe
View article: Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience Open
Purpose. To evaluate the effect of teriparatide (TPTD) on bone mineral density (BMD) and bone markers under clinical practice conditions. To assess whether the results in real-life match those published in clinical trials. Methods. Cross-s…
View article: El laboratorio bioquímico en los desórdenes óseos esclerosantes: Creatinquinasa y osteopetrosis
El laboratorio bioquímico en los desórdenes óseos esclerosantes: Creatinquinasa y osteopetrosis Open
Introducción: la osteopetrosis (enfermedad de huesos de mármol) es un raro tipo de displasia ósea esclerosante caracterizada por una alteración en el funcionamiento / morfología del osteoclasto, lo que conduce a un defecto en la resorción …
View article: Severe Bone Microarchitecture Impairment in Women With Pregnancy and Lactation-Associated Osteoporosis
Severe Bone Microarchitecture Impairment in Women With Pregnancy and Lactation-Associated Osteoporosis Open
Context Pregnancy- and lactation-associated osteoporosis (PLO) is a rare condition characterized by fragility fractures, mostly vertebral, during the third trimester of pregnancy or the early postpartum period. Objective The aim of this st…
View article: Pegvisomant in acromegaly: a multicenter real-life study in Argentina
Pegvisomant in acromegaly: a multicenter real-life study in Argentina Open
Objective To describe the long term safety and efficacy of pegvisomant (PEGV), and the predictors of treatment response in patients with acromegaly in the real life setting. Subjects and methods We retrospectively reviewed the clinical, ho…
View article: Pegvisomant in acromegaly: a multicenter real-life study in Argentina
Pegvisomant in acromegaly: a multicenter real-life study in Argentina Open
this long term experience indicates PEGV treatment was highly effective and safe in our series of Argentine patients with acromegaly refractory to standard therapies. Arch Endocrinol Metab. 2019;63(4):320-7.